Insulet (PODD) Cash & Equivalents Growth (1y) (2011 - 2026)

Insulet (PODD) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (1y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn 4.15%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 24.05%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn -12.13%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 100.41%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -22.13%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 23.57%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -7.71%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -10.02%
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 141.82%
10 Insulet 11.52 Bn 11.04 Bn 529.10 Mn -62.56%

Historic Data

Download Data
DateValue
Mar 31, 2026 -62.56%
Dec 31, 2025 -24.89%
Sep 30, 2025 -16.09%
Jun 30, 2025 36.61%
Mar 31, 2025 70.81%
Dec 31, 2024 35.39%
Sep 30, 2024 31.69%
Jun 30, 2024 24.38%
Mar 31, 2024 21.02%
Dec 31, 2023 4.37%
Sep 30, 2023 -5.07%
Jun 30, 2023 -6.84%
Mar 31, 2023 -12.53%
Dec 31, 2022 -14.77%
Sep 30, 2022 -15.71%
Jun 30, 2022 -17.08%
Mar 31, 2022 -13.54%
Dec 31, 2021 -12.74%
Sep 30, 2021 2.21%
Jun 30, 2021 9.69%